Immune-Onc Therapeutics
Biotechnology ResearchCalifornia, United States11-50 Employees
Immune-Onc Therapeutics is a private biotechnology company headquartered in Palo Alto, California, focused on discovering and developing therapies that target inhibitory receptors on myeloid cells. Its pipeline concentrates on the Leukocyte Immunoglobulin-Like Receptor B (LILRB) family, pursuing an approach aimed at modulating the immune environment to treat cancer. The company has several lead assets in clinical development, including IO-108, which targets LILRB2, and IO-202, which targets LILRB4, along with additional programs in the works. Immune-Onc operates in oncology and immunotherapy, with the goal of addressing tumor-associated myeloid cell inhibition to enhance anti-tumor responses. It advances through early clinical development, with IO-202 in Phase 1b for AML, CMML, and solid tumors, and IO-108 in Phase 1b/2 for solid tumors. In 2024, Immune-Onc announced an oral presentation at the American Society of Hematology Annual Meeting to share data from the IO-202 Phase 1b study in CMML.
1-888-653-2347 
support@leadiq.com 
